Stocktwits on MSN
SLS stock pops after-hours as loss shrinks, cash swells — all eyes on high stakes AML trial in 'pivotal' 2026
Net loss in FY25 narrowed to $26.9 million from $30.9 million a year ago, with R&D costs falling to $16 million. ・Phase 3 Regal AML trial nears final analysis, with 72 of 80 required survival events ...
Stocktwits on MSN
SLS stock jumps overnight: ‘potent’ AML drug data ahead of cancer summit fuels fresh momentum
The company flagged “potent” preclinical data for its AML drug SLS009 ahead of the AACR 2026 conference. ・CEO Angelos ...
The MarketWatch News Department was not involved in the creation of this content. Vancouver, British Columbia--(Newsfile Corp. - February 26, 2026) - AML Incubator (AMLI) today announced the launch of ...
From a study that analyzed the therapeutic dilemma of treating acute leukemia (AL) during pregnancy and the delicate balance of improving maternal and fetal outcomes, investigators determined that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results